A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma

Pigment Cell Melanoma Res. 2016 Jan;29(1):101-3. doi: 10.1111/pcmr.12394. Epub 2015 Aug 20.

Affiliations

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
² Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN, USA.
³ Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
⁴ Division of Surgical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.

PMID: 26176864
DOI: 10.1111/pcmr.12394

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab / adverse effects
Bevacizumab / therapeutic use*
Disease-Free Survival
Erlotinib Hydrochloride / adverse effects
Erlotinib Hydrochloride / therapeutic use*
Humans
Melanoma / drug therapy*
Melanoma / pathology*
Neoplasm Metastasis
Treatment Outcome

Substances

Bevacizumab
Erlotinib Hydrochloride

Grants and funding